There’s Something Awry at Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL) Since Share Price Gets Ahead of Fundamentals

Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL) shares traded -1.96% lower at $10.00 on Wall Street last session.

ZNTL stock price is now -50.68% away from the 50-day moving average and -55.60% away from the 200-day moving average. The market capitalization of the company currently stands at $706.10M.

With the price target reduced from $38 to $12, Wedbush Downgraded its rating from Outperform to Neutral for Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL).

In other news, Brownstein Carrie, Chief Medical Officer sold 10,628 shares of the company’s stock on Oct 04. The stock was sold for $207,298 at an average price of $19.50. Upon completion of the transaction, the Chief Medical Officer now directly owns 105,685 shares in the company, valued at $1.06 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Oct 04, Chief Scientific Officer Bunker Kevin D. sold 6,068 shares of the business’s stock. A total of $118,355 was realized by selling the stock at an average price of $19.50. This leaves the insider owning 859,089 shares of the company worth $8.59 million. Insiders disposed of 215,259 shares of company stock worth roughly $2.15 million over the past 1 year. A total of 9.29% of the company’s stock is owned by insiders.

Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) opened at $10.03 on Wednesday. During the past 12 months, Zentalis Pharmaceuticals Inc has had a low of $9.74 and a high of $31.46. As of last week, the company has a debt-to-equity ratio of 0.09, a current ratio of 8.97, and a quick ratio of 8.97. The fifty day moving average price for ZNTL is $20.27 and a two-hundred day moving average price translates $22.52 for the stock.

The latest earnings results from Zentalis Pharmaceuticals Inc (NASDAQ: ZNTL) was released for Sep, 2023. According to the Biotechnology Company, earnings per share came in at -$1.85, missing analysts’ expectations of -$1.04 by -0.81. This compares to -$0.96 EPS in the same period last year. The company reported revenue of $62.72 million for the quarter, compared to $54.19 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 15.73 percent.

Zentalis Pharmaceuticals Inc(ZNTL) Company Profile

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company’s products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics: and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.

Related Posts